Drug updated on 5/14/2024
Dosage Form | Injection (intramuscular; 10 mg/6 mL, 20 mg/6mL, 30 mg/6mL) |
Drug Class | Somatostatin analogs |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment in patients who have responded to and tolerated Sandostatin Injection subcutaneous injection for acromegaly.
- Indicated for the treatment in patients who have responded to and tolerated Sandostatin Injection subcutaneous injection for severe diarrhea/flushing episodes associated with metastatic carcinoid tumors.
- Indicated for the treatment in patients who have responded to and tolerated Sandostatin Injection subcutaneous injection for profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors.
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Octreotide acetate (Sandostatin LAR Depot) is used for the treatment of acromegaly, severe diarrhea/flushing episodes associated with metastatic carcinoid tumors, and profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors.
- Three systematic reviews/meta-analyses were reviewed that discussed the use and effectiveness of octreotide acetate in various clinical scenarios.
- One review evaluated the efficiency of octreotide in stopping post-surgical Chyle Leak in neck dissection patients, finding it to be an effective way to manage this complication when combined with primary treatment.
- Another study examined its role when combined with other therapies such as everolimus or Peptide Receptor Radionuclide Therapy for neuroendocrine neoplasia management; disease control was observed in 85% cases while progression free survival ranged from 15 to 16.4 months and overall survival from 25 to 61.9 months.
- The third study compared octreotide's effectiveness against oral dietary modification (ODM) for managing chylous fistulae following neck surgery; no significant difference was found between both methods regarding time taken until resolution or rate of spontaneous resolution without need for surgery.
- Across all studies reviewed, Sandostatin LAR Depot showed a good safety profile being well-tolerated by patients experiencing few mild side effects not requiring drug withdrawal; however more robust randomized controlled trials are needed to confirm these findings across different patient populations and indications.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Sandostatin LAR Depot (octreotide acetate) Prescribing Information. | 2023 | Novartis Pharmaceuticals Corporation., East Hanover, NJ |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists. | 2023 | Cancer Treatment Reviews |
A pituitary society update to acromegaly management guidelines. | 2021 | Pituitary |
Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. | 2021 | Journal of the National Comprehensive Cancer Network |
Neuroendocrine tumor theranostics: an update and emerging applications in clinical practice. | 2021 | American Journal of Roentgenology |
Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update. | 2021 | Support Care Cancer |
Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey. | 2020 | Expert Opinion on Pharmacotherapy |